AB0374 End-organ damage in a cohort of filipino patients with systemic lupus erythematosus at two tertiary hospitals
Identifieur interne : 001255 ( Main/Curation ); précédent : 001254; suivant : 001256AB0374 End-organ damage in a cohort of filipino patients with systemic lupus erythematosus at two tertiary hospitals
Auteurs : J. P. C. Consignado ; C. Macapagal [Philippines] ; S. V. Navarra [Philippines]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2013-06.
English descriptors
- Teeft :
- Autoimmune diseases, Combination therapy, Corticosteroid therapy, Cumulative prednisone dose, Damage accrual, Disclosure, Disease activity, Erythematosus, Fetal wastage, Flare, Gran canaria, Important role, Intravenous cyclophosphamide, Irreversible organ damage, Japan background, Limited evidence, Lupus, Lupus nephritis, Maintenance phase, Medical center, Oral prednisone, Outcome measures, Pregnant women, Prospective study, Rheumatoid arthritis, Rituximab, Rituximab treatment, Santo tomas, Scientific abstracts, Spanish society, Systematic review, Systemic, Systemic lupus erythematosus, Tertiary hospitals, Thrombotic thrombocytopenic purpura.
Abstract
Objectives: Objective The study aims to describe the prevalence of end-organ damage in a cohort of systemic lupus erythematosus (SLE) patients at two tertiary hospitals and determine any association of SLE manifestations, medications and end-organ damage. Methods: Design Data of adult (≥18 years old) patients seen at the lupus clinics of two tertiary hospitals (University of Santo Tomas, St. Luke’s Medical Center) from January to June 2012 was assessed using the Systemic Lupus International Collaborating Clinics/SLE Damage Index (SLICC/SDI). Medical records were reviewed for SLE characteristics, American College of Rheumatology (ACR) presenting manifestations of SLE, cumulative steroid dose, and immunosuppressive agents. T test, Fisher’s Exact test, univariate and multivariate analysis were utilized for data analysis. Results: Results. 187 SLE patients (177, 94.7% females), with mean age at diagnosis at 29±10.75 years and mean disease duration of 9±6.7 years were included in the study. 108 (57.7%) had at least 1 end-organ damage. Common end-organ damage were steroid-induced cataract, proteinuria, and stroke in 25 (23%), 22 (20%), and 14 (13%) patients respectively. Damage occurred at an average of 6.6 years after diagnosis. Development of subsequent end-organ damage occurred at an average of 3 years after the preceding damage. Presenting manifestations at SLE diagnosis of proteinuria (p=0.024), anemia (p=0.028), and thrombocytopenia (p=0.049) and immunosuppressive treatment with cyclophosphamide (p=0.046) and cumulative prednisone dose of more than 10 grams (p=0.043) were significantly associated with damage. Conclusions: Conclusion. In this cohort of SLE patients, majority were found to have at least one end-organ damage, most commonly steroid-induced cataract, proteinuria, and stroke. Presenting manifestations of proteinuria, anemia, and thrombocytopenia were significantly associated with damage, reflecting a high disease activity that required increased doses of glucocorticoids. Of the therapies, cylophosphamide and a cumulative prednisone dose ≥ 10 grams were significantly associated with development of end-organ damage. Disclosure of Interest None Declared
Url:
DOI: 10.1136/annrheumdis-2013-eular.2696
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001315
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :001315
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000307
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :001256
Links to Exploration step
ISTEX:D7A53D6078DBDF33541E5A73A1A49B488BC70DDCCuration
No country items
J. P. C. Consignado<affiliation><wicri:noCountry code="subField">City</wicri:noCountry>
</affiliation>
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">AB0374 End-organ damage in a cohort of filipino patients with systemic lupus erythematosus at two tertiary hospitals</title>
<author><name sortKey="Consignado, J P C" sort="Consignado, J P C" uniqKey="Consignado J" first="J. P. C." last="Consignado">J. P. C. Consignado</name>
</author>
<author><name sortKey="Macapagal, C" sort="Macapagal, C" uniqKey="Macapagal C" first="C." last="Macapagal">C. Macapagal</name>
</author>
<author><name sortKey="Navarra, S V" sort="Navarra, S V" uniqKey="Navarra S" first="S. V." last="Navarra">S. V. Navarra</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:D7A53D6078DBDF33541E5A73A1A49B488BC70DDC</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1136/annrheumdis-2013-eular.2696</idno>
<idno type="url">https://api.istex.fr/ark:/67375/NVC-BKNCHRHM-0/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001315</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001315</idno>
<idno type="wicri:Area/Istex/Curation">001315</idno>
<idno type="wicri:Area/Istex/Checkpoint">000307</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000307</idno>
<idno type="wicri:doubleKey">0003-4967:2013:Consignado J:ab:end:organ</idno>
<idno type="wicri:Area/Main/Merge">001256</idno>
<idno type="wicri:Area/Main/Curation">001255</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">AB0374 End-organ damage in a cohort of filipino patients with systemic lupus erythematosus at two tertiary hospitals</title>
<author><name sortKey="Consignado, J P C" sort="Consignado, J P C" uniqKey="Consignado J" first="J. P. C." last="Consignado">J. P. C. Consignado</name>
<affiliation></affiliation>
<affiliation><wicri:noCountry code="subField">City</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Macapagal, C" sort="Macapagal, C" uniqKey="Macapagal C" first="C." last="Macapagal">C. Macapagal</name>
<affiliation wicri:level="1"><country xml:lang="fr">Philippines</country>
<wicri:regionArea>Rheumatology, University of Santo Tomas, Manila</wicri:regionArea>
<wicri:noRegion>Manila</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Philippines</country>
<wicri:regionArea>Rheumatology, University of Santo Tomas, Manila</wicri:regionArea>
<wicri:noRegion>Manila</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Navarra, S V" sort="Navarra, S V" uniqKey="Navarra S" first="S. V." last="Navarra">S. V. Navarra</name>
<affiliation wicri:level="1"><country xml:lang="fr">Philippines</country>
<wicri:regionArea>Rheumatology, University of Santo Tomas, Manila</wicri:regionArea>
<wicri:noRegion>Manila</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Philippines</country>
<wicri:regionArea>Rheumatology, University of Santo Tomas, Manila</wicri:regionArea>
<wicri:noRegion>Manila</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of the Rheumatic Diseases</title>
<title level="j" type="abbrev">Ann Rheum Dis</title>
<idno type="ISSN">0003-4967</idno>
<idno type="eISSN">1468-2060</idno>
<imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<date type="published" when="2013-06">2013-06</date>
<biblScope unit="volume">72</biblScope>
<biblScope unit="issue">Suppl 3</biblScope>
<biblScope unit="page" from="A901">A901</biblScope>
</imprint>
<idno type="ISSN">0003-4967</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0003-4967</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Autoimmune diseases</term>
<term>Combination therapy</term>
<term>Corticosteroid therapy</term>
<term>Cumulative prednisone dose</term>
<term>Damage accrual</term>
<term>Disclosure</term>
<term>Disease activity</term>
<term>Erythematosus</term>
<term>Fetal wastage</term>
<term>Flare</term>
<term>Gran canaria</term>
<term>Important role</term>
<term>Intravenous cyclophosphamide</term>
<term>Irreversible organ damage</term>
<term>Japan background</term>
<term>Limited evidence</term>
<term>Lupus</term>
<term>Lupus nephritis</term>
<term>Maintenance phase</term>
<term>Medical center</term>
<term>Oral prednisone</term>
<term>Outcome measures</term>
<term>Pregnant women</term>
<term>Prospective study</term>
<term>Rheumatoid arthritis</term>
<term>Rituximab</term>
<term>Rituximab treatment</term>
<term>Santo tomas</term>
<term>Scientific abstracts</term>
<term>Spanish society</term>
<term>Systematic review</term>
<term>Systemic</term>
<term>Systemic lupus erythematosus</term>
<term>Tertiary hospitals</term>
<term>Thrombotic thrombocytopenic purpura</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract">Objectives: Objective The study aims to describe the prevalence of end-organ damage in a cohort of systemic lupus erythematosus (SLE) patients at two tertiary hospitals and determine any association of SLE manifestations, medications and end-organ damage. Methods: Design Data of adult (≥18 years old) patients seen at the lupus clinics of two tertiary hospitals (University of Santo Tomas, St. Luke’s Medical Center) from January to June 2012 was assessed using the Systemic Lupus International Collaborating Clinics/SLE Damage Index (SLICC/SDI). Medical records were reviewed for SLE characteristics, American College of Rheumatology (ACR) presenting manifestations of SLE, cumulative steroid dose, and immunosuppressive agents. T test, Fisher’s Exact test, univariate and multivariate analysis were utilized for data analysis. Results: Results. 187 SLE patients (177, 94.7% females), with mean age at diagnosis at 29±10.75 years and mean disease duration of 9±6.7 years were included in the study. 108 (57.7%) had at least 1 end-organ damage. Common end-organ damage were steroid-induced cataract, proteinuria, and stroke in 25 (23%), 22 (20%), and 14 (13%) patients respectively. Damage occurred at an average of 6.6 years after diagnosis. Development of subsequent end-organ damage occurred at an average of 3 years after the preceding damage. Presenting manifestations at SLE diagnosis of proteinuria (p=0.024), anemia (p=0.028), and thrombocytopenia (p=0.049) and immunosuppressive treatment with cyclophosphamide (p=0.046) and cumulative prednisone dose of more than 10 grams (p=0.043) were significantly associated with damage. Conclusions: Conclusion. In this cohort of SLE patients, majority were found to have at least one end-organ damage, most commonly steroid-induced cataract, proteinuria, and stroke. Presenting manifestations of proteinuria, anemia, and thrombocytopenia were significantly associated with damage, reflecting a high disease activity that required increased doses of glucocorticoids. Of the therapies, cylophosphamide and a cumulative prednisone dose ≥ 10 grams were significantly associated with development of end-organ damage. Disclosure of Interest None Declared</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001255 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001255 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:D7A53D6078DBDF33541E5A73A1A49B488BC70DDC |texte= AB0374 End-organ damage in a cohort of filipino patients with systemic lupus erythematosus at two tertiary hospitals }}
![]() | This area was generated with Dilib version V0.6.33. | ![]() |